Trial Profile
A Phase II Study of Lonafarnib in Patients With Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2016
Price :
$35
*
At a glance
- Drugs Lonafarnib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Nov 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Nov 2008 New trial record.